PLK1-IN-4 是一种有效且具有选择性的 PLK1 抑制剂(IC50 < 0.508 nM),对多种癌细胞具有广泛的抗增殖活性,可诱导有丝分裂阻滞于 G2/M 期检查点并导致癌细胞凋亡 (apoptosis),可用于肝细胞癌的研究。
产品编号: MS-X77927 CAS No.: 2622273-55-4 分子式: C24H25F3N6O4S 分子量: 550.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PLK1-IN-4 是一种有效且具有选择性的 PLK1 抑制剂(IC50 < 0.508 nM),对多种癌细胞具有广泛的抗增殖活性,可诱导有丝分裂阻滞于 G2/M 期检查点并导致癌细胞凋亡 (apoptosis),可用于肝细胞癌的研究。

生物实验数据

生物活性 PLK1-IN-4 is a potent and selective PLK1 inhibitor (IC50 < 0.508 nM) that exhibits broad antiproliferative activity against multiple cancer cell lines, induces mitotic arrest at the G2/M checkpoint leading to cancer cell apoptosis, and can be used for the study of hepatocellular carcinoma.
IC50 & Target PLK1:< 0.508 nM
体外研究
(In Vitro)

PLK1-IN-4 (compound 31) (0-5 μM; 48 hours) exhibits excellent antiproliferative activities against HCC cells.
PLK1-IN-4 (60 and 100 nM; 24 hours) induces abnormal spindle formation in HepG2 and HT-29 cells.
PLK1-IN-4 (10-300 nM; 0-48 hours) induces apoptosis in cancer cells through G2/M arrest.
PLK1-IN-4 (0-120 nM; 24 hours) increases phosphorylation of PLK1, histone H3 and NPM and decreases phosphorylation of Cdc2 in a dose-dependent manner.

Cell Proliferation Assay

Cell Line: MDA-MB-231, HeLa, HCT 116, HT-29, HepG2, SMMC7721, A549,JeKo-1,K562, Karpas299, A375, DU-145 and L02
Concentration: 0-5 μM
Incubation Time: 48 hours
Result: Exhibited excellent antiproliferative activities against HCC cells, with IC50s of 11.1 nM and 70.9 nM in HepG2 and SMMC7721 cells.

Cell Cycle Analysis

Cell Line: HepG2
Concentration: 10, 30, 60, 100 and 300 nM
Incubation Time: 0, 12, 24, 36 and 48 hours
Result: Induced apoptosis in cancer cells through G2/M arrest.

Western Blot Analysis

Cell Line: HepG2
Concentration: 0, 10, 30, 60, 90 and 120 nM
Incubation Time: 24 hours
Result: Increased phosphorylation of PLK1, histone H3 and NPM and decreased phosphorylation of Cdc2 in a dose-dependent manner.
体内研究
(In Vivo)

PLK1-IN-4 exhibits low metabolic stability in species of human, mouse, dog and monkey, with CLhep of 74.3, 330.9, 61.5 and 196.5 mL/min/kg, respectively.
PLK1-IN-4 (30 mg/kg; tail vein injection; once or twice daily, for 12 days) suppresses tumor growth in a dose dependent manner.
Pharmacokinetic Parameters of PLK1-IN-4 in male ICR mouse.

IV (5 mg/kg)
C0 (ng/mL) 1790
T1/2 (h) 1.47
MRT0-inf (h) 0.808
MRT0-t (h) 0.704
AUC0-t (ng·h/mL) 767
AUC0-inf (ng·h/mL) 776
CL (mL/min/kg) 107
VdSS (L/kg) 107

Animal Model: Male nu/nu BALB/c mice (4-6 weeks; injected with HepG2 cells)
Dosage: 30 mg/kg
Administration: Tail vein injection; once or twice daily, for 12 days
Result: Suppressed tumor growth in a dose dependent manner, and the tumor growth inhibition (TGI) values were 120.0% and 135.2% at doses of 30 mg/kg once daily and 30 mg/kg twice daily, respectively.
Animal Model: ICR mouse
Dosage: 5 mg/kg
Administration: IV; single (Pharmacokinetics Analysis)
Result: Exhibited a short half-life (T1/2) of 1.47 h, moderate exposure with an area under the curve (AUC0-inf) of 776 ng·h/mL and volume of distribution at steady state (Vdss) of 5.21 L/kg.

化学信息

分子量 550.55
分子式 C24H25F3N6O4S
CAS No. 2622273-55-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础